Defective recombinant adenoviruses expressing cytokines for antitumor treatment
US7306793B2 · kind B2 · utility
7Cited by
3References
9Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Sep 13, 2004 |
| Grant date | Dec 11, 2007 |
| Priority date | — |
| Expiry date | Apr 28, 2025 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2710/10343
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A recombinant nucleic acid used for the production of a defective adenovirus containing an inserted sequence coding for a cytokine under the control of a promoter in the genomic sequence of the recombinant adenovirus. This recombinant adenovirus is useful in the preparation of anti-tumoral drugs which can be directly injected into the tumor of the host.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.